Novavax Granted Fast Track Designation by FDA for COVID-19 Vaccine
Pharmaceutical company Novavax announced on Monday that it has been granted a fast track designation for its COVID-19 vaccine candidate by the Food and Drug Administration (FDA), according to MarketWatch.
The company’s vaccine candidate will be expedited with the help of the government agency in a bid to accelerate the development of an effective and safe COVID-19 vaccine.
Officials at Novavax expect its candidate, called NVXCoV2373, to complete its phase 3 trials based in the U.S. and Mexico by the end of November.
“While the regulatory review of this clinical program will be expedited, Novavax remains committed to a data-driven and scientifically rigorous approach in demonstrating safety and efficacy, which we believe will support confidence in the vaccine in the U.S. and globally,” Gregory M. Glenn, president of Novavax Research and Development, said in a statement.
